CTLA4 and melanoma: Symptomatic radiation necrosis has been reported in patients treated with stereotactic radiosurgery (SRS) plus ICI therapy, especially melanoma (Martin et al., 2018), while murine models first revealed that fractionated stereotactic body radiotherapy (SBRT) schedules enable a more sustained abscopal effect than single 20 Gy fraction RT in combination with anti-CTLA-4 antibody (Dewan et al., 2009).